← Back to Search

PrEP Promotion Messages for HIV/AIDS

N/A
Waitlist Available
Led By Cui Yang, PhD
Research Sponsored by Johns Hopkins Bloomberg School of Public Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
18 years and older
Biological male sex at birth
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30-day follow up
Awards & highlights
No Placebo-Only Group

Summary

This trial will test whether neuroimaging can help assess how effective HIV prevention messages are for MSM.

Who is the study for?
This trial is for biological males at birth, HIV negative, who've never taken PrEP, are 18 or older, live in/near Baltimore City, and have been sexually active with men. They must be at risk of HIV (e.g., condomless sex or recent STI). Those who joined the open contest can't participate.
What is being tested?
The study tests how effective different PrEP promotion messages are for preventing HIV in high-risk men. One set of messages is created through an open contest; another set uses a social marketing approach. Their impact will be evaluated using neuroimaging techniques.
What are the potential side effects?
Since this trial focuses on evaluating promotional messages rather than medical treatments, there aren't direct side effects like those associated with drugs or medical procedures.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I was born male.
Select...
I have never taken PrEP medication.
Select...
I have been sexually active with men in the last 6 months.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30-day follow up
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30-day follow up for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change of Willingness to Take PrEP
Secondary study objectives
PrEP action and initiation

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Open contest messagesExperimental Treatment1 Intervention
Participants will view the top PrEP-promotion messages developed via an open contest.
Group II: Social marketing messagesActive Control1 Intervention
Participants will view the PrEP-promotion messages developed via social marketing.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PrEP campaign messages developed via open contest
2019
N/A
~30

Find a Location

Who is running the clinical trial?

National Institute of Mental Health (NIMH)NIH
2,910 Previous Clinical Trials
2,738,987 Total Patients Enrolled
Johns Hopkins Bloomberg School of Public HealthLead Sponsor
425 Previous Clinical Trials
2,127,224 Total Patients Enrolled
Cui Yang, PhDPrincipal InvestigatorJohns Hopkins Bloomberg School of Public Health
2 Previous Clinical Trials
2,700 Total Patients Enrolled

Media Library

PrEP campaign messages developed via open contest Clinical Trial Eligibility Overview. Trial Name: NCT04166851 — N/A
HIV/AIDS Research Study Groups: Open contest messages, Social marketing messages
HIV/AIDS Clinical Trial 2023: PrEP campaign messages developed via open contest Highlights & Side Effects. Trial Name: NCT04166851 — N/A
PrEP campaign messages developed via open contest 2023 Treatment Timeline for Medical Study. Trial Name: NCT04166851 — N/A
~4 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top